NASDAQ:BLRX BioLineRx (BLRX) Stock Price, News & Analysis → Who are Nvidia’s Silent Partners? (From Weiss Ratings) (Ad) Free BLRX Stock Alerts $0.62 0.00 (0.00%) (As of 05/22/2024 ET) Add Compare Share Share Today's Range$0.60▼$0.6350-Day Range$0.58▼$1.3852-Week Range$0.55▼$2.53Volume176,270 shsAverage Volume373,995 shsMarket Capitalization$49.56 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BioLineRx alerts: Email Address BioLineRx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside3,287.1% Upside$21.00 Price TargetShort InterestHealthy0.51% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.03) to ($0.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.85 out of 5 starsMedical Sector621st out of 920 stocksPharmaceutical Preparations Industry270th out of 399 stocks 3.5 Analyst's Opinion Consensus RatingBioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioLineRx has only been the subject of 1 research reports in the past 90 days.Read more about BioLineRx's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.51% of the outstanding shares of BioLineRx have been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioLineRx has recently decreased by 47.60%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioLineRx does not currently pay a dividend.Dividend GrowthBioLineRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLRX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for BioLineRx this week, compared to 1 article on an average week.Search Interest7 people have searched for BLRX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLineRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of BioLineRx is held by insiders.Percentage Held by InstitutionsOnly 1.56% of the stock of BioLineRx is held by institutions.Read more about BioLineRx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLineRx are expected to grow in the coming year, from ($1.03) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLineRx is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLineRx is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLineRx has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about BioLineRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubThe 7th Trillion Dollar Company?There are six American companies worth more than $1 trillion currently. But is there going to be a 7th trillion dollar company soon?This company just signed a MASSIVE deal with Apple. About BioLineRx Stock (NASDAQ:BLRX)BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Read More BLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLRX Stock News HeadlinesMay 22 at 7:09 AM | finance.yahoo.comBioLineRx to Report First Quarter 2024 Results on May 28, 2024May 22 at 7:00 AM | prnewswire.comBioLineRx to Report First Quarter 2024 Results on May 28, 2024May 17, 2024 | prnewswire.comBioLineRx Announces Receipt of Nasdaq Minimum Bid Price NotificationMay 6, 2024 | prnewswire.comBioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024April 18, 2024 | markets.businessinsider.comBuy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis EfficiencyApril 17, 2024 | finance.yahoo.comBioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual MeetingApril 11, 2024 | investing.comBioLineRx secures $20 million in BlackRock financingApril 10, 2024 | finance.yahoo.comBioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing AgreementApril 10, 2024 | prnewswire.comBioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing AgreementApril 1, 2024 | prnewswire.comBioLineRx Announces $6 Million Registered Direct OfferingMarch 28, 2024 | finanznachrichten.deBioLineRx Ltd.: BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio UpdatesMarch 27, 2024 | finance.yahoo.comBioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comBLRX: First Aphexda Sales RecognizedMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioLineRx: Strong Financials and Expanding Market Presence Fuel Analyst OptimismMarch 26, 2024 | prnewswire.comBioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio UpdatesMarch 20, 2024 | prnewswire.comBioLineRx to Report 2023 Annual Financial Results on March 26, 2024March 4, 2024 | finance.yahoo.comBioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale ProductionMarch 1, 2024 | investing.comBioLineRx begins phase 2 trial for pancreatic cancer treatmentMarch 1, 2024 | finance.yahoo.comBLRX Mar 2024 1.000 callFebruary 28, 2024 | prnewswire.comBioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)February 26, 2024 | finance.yahoo.comBLRX: Poster PresentationsFebruary 25, 2024 | investorplace.com3 Top Penny Stocks for 5,000% Upside in 2024 and BeyondFebruary 23, 2024 | ca.finance.yahoo.comBLRX May 2024 1.000 putFebruary 16, 2024 | finance.yahoo.comBioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®February 16, 2024 | prnewswire.comBioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®See More Headlines Receive BLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/22/2024Next Earnings (Estimated)5/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BLRX CUSIPN/A CIK1498403 Webwww.biolinerx.com Phone(728) 642-9100Fax972-8642-9101Employees79Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+3,342.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,610,000.00 Net MarginsN/A Pretax Margin-1,262.79% Return on Equity-280.21% Return on Assets-99.22% Debt Debt-to-Equity Ratio0.50 Current Ratio1.53 Quick Ratio1.47 Sales & Book Value Annual Sales$4.80 million Price / Sales10.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book3.39Miscellaneous Outstanding Shares79,940,000Free Float79,060,000Market Cap$48.77 million OptionableOptionable Beta1.50 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Philip A. Serlin CPA (Age 64)M.B.A., CPA, MBA, Chief Executive Officer Comp: $598kMs. Mali Zeevi CPA (Age 48)CPA, Chief Financial Officer Comp: $374kDr. Ella Sorani Ph.D. (Age 56)Chief Development Officer Comp: $452kMs. Holly W. May M.B.A. (Age 62)President of BioLineRx USA Comp: $710kMr. John LaceyHead of Corporate Communications & Investor RelationsMs. Tsipi Keren-Lehrer B.Sc.L.L.B., Head of BD & Strategic AdvisorMr. Raziel FriedTreasurer & Budgetary Control DirectorMore ExecutivesKey CompetitorsCleneNASDAQ:CLNNNextCureNASDAQ:NXTCEquilliumNASDAQ:EQXilio TherapeuticsNASDAQ:XLOImmuneeringNASDAQ:IMRXView All CompetitorsInstitutional OwnershipPVG Asset Management CorpBought 61,840 shares on 3/12/2024Ownership: 0.085%View All Institutional Transactions BLRX Stock Analysis - Frequently Asked Questions Should I buy or sell BioLineRx stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLRX shares. View BLRX analyst ratings or view top-rated stocks. What is BioLineRx's stock price target for 2024? 1 Wall Street research analysts have issued twelve-month target prices for BioLineRx's stock. Their BLRX share price targets range from $21.00 to $21.00. On average, they expect the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 3,287.1% from the stock's current price. View analysts price targets for BLRX or view top-rated stocks among Wall Street analysts. How have BLRX shares performed in 2024? BioLineRx's stock was trading at $1.57 at the start of the year. Since then, BLRX stock has decreased by 60.5% and is now trading at $0.62. View the best growth stocks for 2024 here. When is BioLineRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our BLRX earnings forecast. How were BioLineRx's earnings last quarter? BioLineRx Ltd. (NASDAQ:BLRX) released its quarterly earnings results on Thursday, March, 28th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. The biotechnology company earned $4.80 million during the quarter, compared to analysts' expectations of $0.17 million. During the same quarter in the previous year, the firm earned ($0.09) earnings per share. What other stocks do shareholders of BioLineRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Who are BioLineRx's major shareholders? BioLineRx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of BioLineRx? Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLRX) was last updated on 5/22/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media41 banks launch ‘crypto dollar’Stansberry ResearchTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademySeven unknown AI stocks that could DOMINATE the next six years.The Oxford Club[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
